ISSN: 2157-7552 Open Access

Whole-Cell Dissociated Suspension Analysis in Human Brain Neurodegenerative Disease: A Pilot Study

Geidy E Serrano¹, Jessica E Walker¹, Anthony J Intorcia¹, Michael J Glass¹, Richard A Arce¹, Ignazio S. Piras^{2,3}, Joshua S Talboom^{2,3}, Courtney M Nelson¹, Brett D Cutler¹, Lucia I Sue¹, Lih-Fen Lue¹, Matthew Huentelman^{2,3} and Thomas G Beach¹

¹Banner Sun Health Research Institute, Arizona, United States

Abstract

Biochemical analysis of human brain tissue is typically done by homogenizing whole pieces of brain and separately characterizing the proteins, RNA, DNA, and other macromolecules within. While this has been sufficient to identify substantial changes, there is little ability to identify small changes or alterations that may occur in subsets of cells. To effectively investigate the biochemistry of disease in the brain, with its different cell types, we must first separate the cells and study them as phenotypically defined populations or even as individuals. In this project, we developed a new method for the generation of Whole Cell Dissociated Suspensions (WCDS) in fresh human brain tissue that could be shared as a resource with scientists to study single human cells or populations. Characterization of WCDS was done in paraffin-embedded sections stained with H&E, and by phenotyping with antibodies using immunohistochemistry and Fluorescence Activated Cell Sorting (FACS). Additionally, we compared extracted RNA from WCDS with RNA from adjacent intact cortical tissue, using RT-qPCR for cell-type-specific RNA for the same markers as well as whole transcriptome sequencing. More than 11,626 gene transcripts were successfully sequenced and classified using an external database either as being mainly expressed in neurons, astrocytes, microglia, oligodendrocytes, endothelial cells, or mixed (in two or more cell types). This demonstrates that we are currently capable of producing WCDS with a full representation of different brain cell types combined with RNA quality suitable for use in biochemical analysis.

Keywords: Single-cell • RNA-seq • Human brain • Fluorescence-activated cell sorting

Introduction

Biochemical analysis of human neurodegenerative brain tissue and animal models have produced much of what is known about these conditions and has led to FDA-approved therapies. The typical approach has been to homogenize whole pieces of frozen brain tissue and separately characterize the proteins, RNA, DNA, and other macromolecules within. However, many recent studies have recognized challenges in finding small biochemical changes that could occur in specific subsets of cells in the diseased brain. Furthermore, neurodegenerative disease often leads to massive losses of the disease-targeted cells; for example, the entorhinal cortex layer II stellate neurons or substantia nigra pigmented neurons. Whole-homogenate analysis of such brain regions can generate misleading results, as any biochemical constituent that is selectively localized to the depleted cells will appear to be "down-regulated". Also a relevant loss or increase might be missed entirely if the biochemical entity is found in many cell types, diluting the 'lost' signal from the cell of interest, especially if that cell type is uncommon or rare. To effectively investigate the biochemistry of neurodegenerative disease in the brain, with its thousands of different cell types, we must first separate the cells and study them as phenotypicallydefined populations, and even as individuals.

Laser Capture Microscopy (LCM) is a method that can pick individual cells from a cryostat section for characterization. However, this technology

*Address for Correspondence: Dr. Geidy E Serrano, Banner Sun Health Research Institute, Arizona, United States; Tel: +623-832-5608; Email: Geidy. Serrano@bannerhealth.com

Copyright: © 2021 Serrano GE, et al. This is an open-access article distributed under the terms of the creative commons attribution license which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Received date: September 22, 2021; Accepted date: October 06, 2021; Published date: October 13, 2021

is limited by the considerable time and personnel investment as well as the limited ability to mark target cells phenotypically prior to microdissection. In recent years, methods have been developed that allow an initial creation of single-cell suspensions [1-3]. Or single nuclei isolation from solid fixed, fresh or frozen tissue [5-7]. Followed by the analysis of phenotypicallydefined cells sorted based on cell-type identifying proteins or RNA expression. These methods are much more time and labor-efficient than LCM and allow sorting by a much more diverse panel of markers. Studies suggest that even though comparable, nuclear mRNA is present at only 20-50% abundance compared to that present in whole cells [4, 6]. Some groups have already published intriguing results from Alzheimer's Disease (AD) brain nuclei [7-10]. But to our knowledge only one study isolated whole cells from frozen human AD brains [1]. In this study we explored a new methodology to create Whole Cell Dissociated Suspensions (WCDS) from rapidly autopsied human brains, with the primary goal of sharing this new resource with researchers interested in studying cell-type-specific changes in aging and aging-related disorders. We analyzed possible changes that could be induced by cell isolation and suggest that our WCDS resource could help uncover cell-specific changes of aging.

Materials and Methods

Whole-cell-dissociated-suspension preparation

Fresh brain samples came from subjects who were volunteers in the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND) and the Brain and Body Donation Program (BBDP; www. brainandbodydonationprogram.org), a longitudinal clinicopathological study of healthy aging, cognition, and movement in the elderly since 1996 in Sun City, Arizona [11,12]. This study was approved by Western IRB in Puyallup, Washington (#230120821, 08/02/2020). In addition, all subjects signed an Institutional Review Boardapproved informed consent reviewed by the Western IRB in Puyallup, Washington (#230120821, 08/02/2020), allowing both clinical assessments during life and several options for brain and bodily organ donation after death. No clinical data was used for this study

²Translational Genomics Research Institute, Phoenix, USA

³Institute of Arizona Alzheimer's Consortium, Phoenix, USA

and all samples were fully anonymized. Cases were selected independently of their clinical diagnosis, but favoring those with the shortest postmortem intervals. Fresh bilateral coronal sections of the frontal lobe were collected just anterior to the genu of the corpus callosum at autopsy and were stored in Hibernate A (Brain bits cat#HA) until processing (<18 hrs). The grey matter was dissected and finely minced in the cold with RNAse later and weighed. Accutase (Innovative cell technologies BE cat#AT104) was used for enzymatic digestion and different incubation times were tested; 0 hrs, 2 hrs, and 4 hrs all at 4°C, followed by mechanical disruption by repetitive pipetting. Homogenates were centrifuged and Accutase was replaced by Hank's balanced salt solution (HBSS), following cell filtration using 100 and 70 µm filters. Myelin, neuropil, and other cellular debris were remove dusing 30% and 70% Percoll (GE Healthcare cat#17-0891-01), while final WCDS

were stored in cryoprotectant solution (90%FBA and 10% DMSO+1U/µl RNAse inhibitor) for future characterization [2].

Histological characterization

Single WCDS aliquots from all cases were fixed in formalin overnight. The day after, fixed WCDS were washed, pelleted, and embedded in paraffin. Serial 3 µm paraffin sections were collected for Hematoxylin and Eosin staining and immunostaining for cell-specific markers. Antibodies targeting cell types included neuronal markers NeuN, MAP2, and neurofilament; astrocyte marker GFAP; and microglia markers IBA1 and LN3 in Table 1. Stained sections were examined by a neuropathologist, who also estimated the percentages of different cell types by nuclear morphologyin 12 WCDS (Table 1) (Figure 1).

Table 1. Inorganic and organic supplements.

Astrocytes Rabbit anti-GFAP [EPR1034Y], Alexa Fluor 488 Synthetic peptide within Human GFAP aa 1-100 (N terminal) Mouse anti-GFAP Alexa Fluor 647 Bovine spinal cord homogenate Biolegend/644706 Mouse anti-GFAP (Clone 1B4) Alexa Fluor 647 Rabbit anti-MAP2 [EPR19691] Recombinant protein Mouse anti-NeuN (Clone A60) Alexa Fluor 488 Purified cell nuclei from mouse Brain Millipore-Sigma/MAB377X Rabbit anti-NeuN [EPR12763] Alexa Fluor 647 Synthetic peptide within Human NeuN aa 1-100 (Cysteine residue) Synthetic peptide within Human NeuN aa 1-100 (Cysteine residue) Abcam/ab190195 Microglia Mouse anti-human HLADR (LN3), Alexa Fluor 488 Microglia Mouse anti-human HLADR (LN3), Alexa Fluor 488 Rabbit anti-BBA1 Rabbit anti-BBA1 [EPR6136(2)] Alexa Fluor 488 Rabbit anti-BBA1 [EPR6136(2)] Alexa Fluor 488 Rabbit anti-BBA1 [EPR6136(2)] Alexa Fluor 488 Rabbit anti-BBA1 [EPR6136(2)] Alexa Fluor 647 Synthetic peptide within Human Iba1 aa 1-100 (Cysteine residue) Synthetic peptide within Human Iba1 aa 1-100 (Cysteine residue) Abcam/ab195032 Synthetic peptide within Human Iba1 aa 1-100 (Cysteine residue) Synthetic peptide within Human Iba1 aa 1-100 (Cysteine residue) Synthetic peptide within Human Iba1 aa 1-100 (Cysteine residue) Abcam/ab195032 Abcam/ab199472 Abcam/ab109186 Significance: Catalog number (#) of each product or antibody.	Cell marker	Primary antibody	Antigen specificity or immunogen	Company /Catalog #
Mouse anti-GFAP (Clone 1B4) Alexa Fluor 647 Cow spinal cord homogenate BD Pharmingen/560298				
Rabbit anti-MAP2 [EPR19691] Recombinant protein Invitrogen/PĀ5-24589 Rabbit anti-MAP2 [EPR19691] Recombinant fragment within Mouse MAP2 aa 650-1000 Abcam/ab183830 Mouse anti-NeuN (Clone A60) Alexa Fluor 488 Purified cell nuclei from mouse Brain Millipore-Sigma/MAB377X Rabbit anti-NeuN [EPR12763] Alexa Fluor 647 Synthetic peptide within Human NeuN aa 1-100 (Cysteine residue) Abcam/ab190565 Rabbit anti-NeuN [EPR12763] Alexa Fluor 488 Synthetic peptide within Human NeuN aa 1-100 (Cysteine residue) Abcam/ab190195 Neurofilament Rabbit anti-NeuN [EPR12763] Alexa Fluor 488 Full-length native protein (purified) corresponding to Cow Neurofilament heavy polypeptide Human PBL Biolegend/327010 Rabbit anti-IBA1 Recombinant protein encompassing a sequence within the center region of human lba1 Rabbit anti-IBA1 [EPR6136(2)] Alexa Fluor 488 Sequence Synthetic peptide within Human lba1 aa 1-100 (Cysteine residue) Synthetic peptide within Human lba1 aa 1-100 (Cysteine residue) Myelin/Oligos Rabbit anti-Myelin oligodendrocyte glycoprotein antibody Synthetic peptide within Human Myelin oligodendrocyte glycoprotein antibody Full-tier peptide within Human Myelin oligodendrocyte glycoprotein antibody Synthetic peptide within Human Myelin oligodendrocyte glycoprotein an 50-150 (extracellular) Myelin/Oligos Rabbit anti-Olig2 [EPR2673] Synthetic peptide within Human Olig2 aa 250-350		Mouse anti-GFAP Alexa Fluor 647	Bovine spinal cord homogenate	Biolegend/644706
Rabbit anti-MAP2 [EPR19691] Recombinant fragment within Mouse MAP2 aa 650-1000 Abcam/ab183830 Mouse anti-NeuN (Clone A60) Alexa Fluor 488 Purified cell nuclei from mouse Brain Millipore-Sigma/MAB377X Rabbit anti-NeuN [EPR12763] Alexa Fluor 647 Synthetic peptide within Human NeuN aa 1-100 (Cysteine residue) Neurofilament Rabbit anti-NeuN [EPR12763] Alexa Fluor 488 Synthetic peptide within Human NeuN aa 1-100 (Cysteine residue) Neurofilament Rabbit anti-Neurofilament heavy polypeptide antibody Full-length native protein (purified) corresponding to Cow Neurofilament heavy polypeptide Microglia Mouse anti-human HLADR (LN3), Alexa Fluor 488 Human PBL Biolegend/327010 Rabbit anti-IBA1 Recombinant protein encompassing a sequence within the center region of human lba1 Synthetic peptide corresponding to the lba1 carboxy-terminal sequence Neurofilament heavy polypeptide Rabbit anti-IBA1 [EPR6136(2)] Alexa Fluor 488 Synthetic peptide within Human lba1 aa 1-100 (Cysteine residue) Nyelin/Oligos Rabbit anti-Myelin oligodendrocyte glycoprotein antibody [EP4281] Alexa Fluor 647 Synthetic peptide within Human Myelin oligodendrocyte glycoprotein aa 50-150 (extracellular) Nyelin (Oligo Septide vithin Human Olig2 aa 250-350)				
Mouse anti-NeuN (Clone A60) Alexa Fluor 488 Rabbit anti-NeuN [EPR12763] Alexa Fluor 647 Rabbit anti-NeuN [EPR12763] Alexa Fluor 488 Synthetic peptide within Human NeuN aa 1-100 (Cysteine residue) Neurofilament Rabbit anti-Neun [EPR12763] Alexa Fluor 488 Neurofilament Rabbit anti-Neun [EPR12763] Alexa Fluor 488 Neurofilament Rabbit anti-Neurofilament heavy polypeptide antibody Full-length native protein (purified) corresponding to Cow Neurofilament heavy polypeptide Microglia Mouse anti-human HLADR (LN3), Alexa Fluor 488 Rabbit anti-IBA1 Rabbit anti-IBA1 Rabbit anti-IBA1 Rabbit anti-IBA1 [EPR6136(2)] Alexa Fluor 488 Rabbit anti-IBA1 [EPR6136(2)] Alexa Fluor 488 Myelin/Oligos Rabbit anti-Myelin oligodendrocyte glycoprotein antibody [EP4281] Alexa Fluor 647 Rabbit anti-Olig2 [EPR2673] Neurofilament heavy polypeptide within Human NeuN aa 1-100 (Cysteine residue) Abcam/ab190195 Abcam/ab190195 Abcam/ab199472 Abcam/ab109186	Neurons	Rabbit anti-MAP2	MAP2 recombinant protein	Invitrogen/PA5-24589
Rabbit anti-NeuN [EPR12763] Alexa Fluor 488 Rabbit anti-NeuN [EPR12763] Alexa Fluor 488 Synthetic peptide within Human NeuN aa 1-100 (Cysteine residue) Synthetic peptide within Human NeuN aa 1-100 (Cysteine residue) Abcam/ab190195 Synthetic peptide within Human NeuN aa 1-100 (Cysteine residue) Neurofilament Rabbit anti-NeuN [EPR12763] Alexa Fluor 488 Microglia Mouse anti-human HLADR (LN3), Alexa Fluor 488 Rabbit anti-IBA1 Rabbit anti-IBA1 Rabbit anti-IBA1 Rabbit anti-IBA1 [EPR6136(2)] Alexa Fluor 488 Rabbit anti-IBA1 [EPR6136(2)] Alexa Fluor 488 Rabbit anti-IBA1 [EPR6136(2)] Alexa Fluor 488 Synthetic peptide corresponding to the Iba1 carboxy-terminal sequence Synthetic peptide within Human Iba1 aa 1-100 (Cysteine residue) Synthetic peptide within Human Iba1 aa 1-100 (Cysteine residue) Myelin/Oligos Rabbit anti-Myelin oligodendrocyte glycoprotein antibody [EP4281] Alexa Fluor 647 Rabbit anti-Olig2 [EPR2673] Synthetic peptide within Human Olig2 aa 250-350 Abcam/ab190565 Abcam/ab190195 Abcam/ab190195 Synthetic peptide within Human NeuN aa 1-100 (Cysteine residue) Abcam/ab19032		Rabbit anti-MAP2 [EPR19691]	Recombinant fragment within Mouse MAP2 aa 650-1000	Abcam/ab183830
Rabbit anti-NeuN [EPR12763] Alexa Fluor 488 Synthetic peptide within Human NeuN aa 1-100 (Cysteine residue) Neurofilament Rabbit anti-Neun [EPR12763] Alexa Fluor 488 Microglia Mouse anti-human HLADR (LN3), Alexa Fluor 488 Rabbit anti-IBA1 Rabbit anti-IBA1 Rabbit anti-IBA1 Rabbit anti-IBA1 Rabbit anti-IBA1 [EPR6136(2)] Alexa Fluor 488 Rabbit anti-IBA1 [EPR6136(2)] Alexa Fluor 488 Rabbit anti-IBA1 [EPR6136(2)] Alexa Fluor 647 Synthetic peptide within Human Iba1 aa 1-100 (Cysteine residue) Myelin/Oligos Rabbit anti-Myelin oligodendrocyte glycoprotein antibody [EP4281] Alexa Fluor 647 Rabbit anti-Olig2 [EPR2673] Rabbit anti-Olig2 [EPR2673] Rabbit anti-Olig2 [EPR2673] Abcam/ab190186		Mouse anti-NeuN (Clone A60) Alexa Fluor 488	Purified cell nuclei from mouse Brain	Millipore-Sigma/MAB377X
Rabbit anti-NeuN [EPR12763] Alexa Fluor 488 Synthetic peptide within Human NeuN aa 1-100 (Cysteine residue) Neurofilament Rabbit antiNeurofilament heavy polypeptide antibody Full-length native protein (purified) corresponding to Cow Neurofilament heavy polypeptide Microglia Mouse anti-human HLADR (LN3), Alexa Fluor 488 Human PBL Recombinant protein encompassing a sequence within the center region of human lba1 Rabbit anti-IBA1 Rabbit anti-IBA1 [EPR6136(2)] Alexa Fluor 488 Rabbit anti-IBA1 [EPR6136(2)] Alexa Fluor 488 Rabbit anti-IBA1 [EPR6136(2)] Alexa Fluor 647 Synthetic peptide within Human lba1 aa 1-100 (Cysteine residue) Synthetic peptide within Human lba1 aa 1-100 (Cysteine residue) Myelin/Oligos Rabbit anti-Myelin oligodendrocyte glycoprotein antibody glycoprotein aa 50-150 (extracellular) Rabbit anti-Olig2 [EPR2673] Synthetic peptide within Human Olig2 aa 250-350		Rabbit anti-NeuN [EPR12763] Alexa Fluor 647		Abcam/ab190565
Neurofilament Rabbit anti-Neurofilament heavy polypeptide antibody Full-length native protein (purified) corresponding to Cow Neurofilament heavy polypeptide Microglia Mouse anti-human HLADR (LN3), Alexa Fluor 488 Human PBL Rabbit anti-IBA1 Recombinant protein encompassing a sequence within the center region of human lba1 Rabbit anti-IBA1 Synthetic peptide corresponding to the lba1 carboxy-terminal sequence Rabbit anti-IBA1 [EPR6136(2)] Alexa Fluor 488 Sequence Rabbit anti-IBA1 [EPR6136(2)] Alexa Fluor 647 Synthetic peptide within Human lba1 aa 1-100 (Cysteine residue) Synthetic peptide within Human lba1 aa 1-100 (Cysteine residue) Myelin/Oligos Rabbit anti-Myelin oligodendrocyte glycoprotein antibody [EP4281] Alexa Fluor 647 Rabbit anti-Olig2 [EPR2673] Synthetic peptide within Human Olig2 aa 250-350 Abcam/ab199472 Abcam/ab109186		Rabbit anti-NeuN [EPR12763] Alexa Fluor 488		Abcam/ab190195
Microglia Mouse anti-human HLADR (LN3), Alexa Fluor 488 Human PBL Biolegend/327010 Rabbit anti-IBA1 Recombinant protein encompassing a sequence within the center region of human Iba1 Wako/016-20001 Rabbit anti-IBA1 [EPR6136(2)] Alexa Fluor 488 Sequence Within Human Iba1 carboxy-terminal sequence Synthetic peptide within Human Iba1 aa 1-100 (Cysteine residue) Myelin/Oligos Rabbit anti-Myelin oligodendrocyte glycoprotein antibody [EP4281] Alexa Fluor 647 Synthetic peptide within Human Myelin oligodendrocyte glycoprotein antibody glycoprotein aa 50-150 (extracellular) Rabbit anti-Olig2 [EPR2673] Synthetic peptide within Human Olig2 aa 250-350			residue)	
Rabbit anti-IBA1 Recombinant protein encompassing a sequence within the center region of human Iba1 Wako/016-20001 Rabbit anti-IBA1 [EPR6136(2)] Alexa Fluor 488 Sequence Synthetic peptide corresponding to the Iba1 carboxy-terminal sequence Abcam/ab195031 Rabbit anti-IBA1 [EPR6136(2)] Alexa Fluor 647 Synthetic peptide within Human Iba1 aa 1-100 (Cysteine residue) Synthetic peptide within Human Iba1 aa 1-100 (Cysteine residue) Myelin/Oligos Rabbit anti-Myelin oligodendrocyte glycoprotein antibody [EP4281] Alexa Fluor 647 Synthetic peptide within Human Myelin oligodendrocyte glycoprotein aa 50-150 (extracellular) Rabbit anti-Olig2 [EPR2673] Synthetic peptide within Human Olig2 aa 250-350	Neurofilament			Abcam/ab8135
Rabbit anti-IBA1 Rabbit anti-IBA1 [EPR6136(2)] Alexa Fluor 488 Rabbit anti-IBA1 [EPR6136(2)] Alexa Fluor 488 Rabbit anti-IBA1 [EPR6136(2)] Alexa Fluor 647 Synthetic peptide within Human Iba1 aa 1-100 (Cysteine residue) Synthetic peptide within Human Iba1 aa 1-100 (Cysteine residue) Synthetic peptide within Human Iba1 aa 1-100 (Cysteine residue) Myelin/Oligos Rabbit anti-Myelin oligodendrocyte glycoprotein antibody [EP4281] Alexa Fluor 647 Rabbit anti-Olig2 [EPR2673] Synthetic peptide within Human Myelin oligodendrocyte glycoprotein aa 50-150 (extracellular) Abcam/ab199472 Abcam/ab109186	Microglia	Mouse anti-human HLADR (LN3), Alexa Fluor 488	Human PBL	Biolegend/327010
Rabbit anti-IBA1 Rabbit anti-IBA1 [EPR6136(2)] Alexa Fluor 488 Rabbit anti-IBA1 [EPR6136(2)] Alexa Fluor 647 Rabbit anti-IBA1 [EPR6136(2)] Alexa Fluor 647 Synthetic peptide within Human Iba1 aa 1-100 (Cysteine residue) Synthetic peptide within Human Iba1 aa 1-100 (Cysteine residue) Synthetic peptide within Human Iba1 aa 1-100 (Cysteine residue) Myelin/Oligos Rabbit anti-Myelin oligodendrocyte glycoprotein antibody [EP4281] Alexa Fluor 647 Rabbit anti-Olig2 [EPR2673] Synthetic peptide within Human Myelin oligodendrocyte glycoprotein aa 50-150 (extracellular) Abcam/ab199472 Abcam/ab109186		Rabbit anti-IBA1		Invitrogen/PA5-27436
Rabbit anti-IBA1 [EPR6136(2)] Alexa Fluor 488 sequence Abcam/ab195031 Rabbit anti-IBA1 [EPR6136(2)] Alexa Fluor 647 Synthetic peptide within Human Iba1 aa 1-100 (Cysteine residue) Synthetic peptide within Human Iba1 aa 1-100 (Cysteine residue) Myelin/Oligos Rabbit anti-Myelin oligodendrocyte glycoprotein antibody [EP4281] Alexa Fluor 647 Synthetic peptide within Human Myelin oligodendrocyte glycoprotein aa 50-150 (extracellular) Abcam/ab195032 Abcam/ab195032 Abcam/ab195032 Abcam/ab195032 Abcam/ab195032 Synthetic peptide within Human Myelin oligodendrocyte glycoprotein aa 50-150 (extracellular) Abcam/ab109186		Rabbit anti-IBA1	·	
residue) Synthetic peptide within Human Iba1 aa 1-100 (Cysteine residue) Myelin/Oligos Rabbit anti-Myelin oligodendrocyte glycoprotein antibody [EP4281] Alexa Fluor 647 Rabbit anti-Olig2 [EPR2673] Synthetic peptide within Human Myelin oligodendrocyte glycoprotein aa 50-150 (extracellular) Abcam/ab109186 Synthetic peptide within Human Olig2 aa 250-350		Rabbit anti-IBA1 [EPR6136(2)] Alexa Fluor 488	, , , , , , , , , , , , , , , , , , , ,	
Myelin/Oligos Rabbit anti-Myelin oligodendrocyte glycoprotein antibody [EP4281] Alexa Fluor 647 Synthetic peptide within Human Myelin oligodendrocyte glycoprotein aa 50-150 (extracellular) Abcam/ab199472 Abcam/ab109186 Synthetic peptide within Human Olig2 aa 250-350		Rabbit anti-IBA1 [EPR6136(2)] Alexa Fluor 647		Abcam/ab195032
[EP4281] Alexa Fluor 647 glycoprotein aa 50-150 (extracellular) Abcam/ab109186 Rabbit anti-Olig2 [EPR2673] Synthetic peptide within Human Olig2 aa 250-350				
Rabbit anti-Olig2 [EPR2673] Synthetic peptide within Human Olig2 aa 250-350	Myelin/Oligos			Abcam/ab199472
				Abcam/ab109186
	0::6:		Synthetic peptide within Human Olig2 aa 250-350	




Figure 1. Characterization of single-cell suspensions by H & E and immunostaining with NeuN, GFAP, and IBA1. Note: Estimation of cell numbers using nuclear morphology (H&E stain, above left) and cell-type-specific markers (in black) suggest that roughly 50% of the cells are neurons (N=neurons), with astrocytes (A=astrocytes), and microglia (M=microglia) each making up about 25% of the total. Oligodendrocytes (O) are relatively rare. Scale bar=10µm.

Cellular-specific marker characterization by fluorescent cell sorting

To further establish the presence of the different human brain cell types in WCDS, fluorescenceactivated cell sorting (FACS; Bio-Rad S3E; with 488 and 647 nm wavelength) was used. Frozen WCDS aliquots were rapidly thawed at 37°C, followed by a 10-minute fixation in 70% methanol, 1mM EDTA, and 1U/µl of RNAse inhibitor [2,13]. Suspensions were permeabilized in a 0.1 M phosphate base solution with 2% Triton X-100 for 10 minutes before primary antibody incubation overnight at 4°C. The Sorting antibodies included neuronal markers NeuN, MAP2, and neurofilament-H, GFAP marker for the activation of astrocytes, and IBA1 for microglia. Multiple antibodies tested were commercially pre-labeled with fluorophores Table 1. Although, we also tested non-fluorescent primary antibodies, which were later incubated with fluorescent dye-labeled secondary antibodies (Molecular Probes goat antimouse and goat anti-rabbit 488 and 647).

RNA isolation and RNA characterization

WCDS aliquots from 30 cases were randomly selected for RNA extraction using Qiagen RNeasy Plus micro (cat#74034,) following the manufacturer's instructions, including their suggested protocol of adding PolyA Carrier RNA. An Agilent Bioanalyzer was used to calculate the average RNA integrity number (RIN) and Thermo Fisher nanodrop to calculate the RNA yield. Following this, WCDS from 12 cases were used to further characterize the samples' transcripts, and were then compared to those expressed in adjacent frozen whole tissue homogenates (WTH) of the same cases. RNA from WTH was extracted using Qiagen RNeasy Plus mini kits (cat# 74134). Reverse transcription for both sets of samples was done using iScript Reverse Transcription Supermix (Bio-Rad cat # 1708841). Before qRT-PCR, samples were subject to preamplification using TaqMan

PreAmp Master Mix 2X (Thermo Fisher cat #4391128) and 0.2x pooled TaqMan Gene Expression Assays (Thermo Fisher cat #4391370). Probes included NeuN (Hs01370654), GFAP (Hs00909233_m1) and IBA1 (Hs00610419_g1), in addition to housekeeping probes: ACTB (Hs01060665_g1), GAPDH (Hs00266705_g1), and 18S (Hs99999901_s1). The amplification mixture was prepared using Sso Advanced Universal Probes Supermix 2X (Bio-Rad cat#1715281) and the previously mentioned TaqMan Gene Expression Assays, which include the forward and reverse primer and fluorogenic probe and preamplified cDNA. qRT-PCR was performed using Bio-Rad CFX Connect. The cycling conditions were an initial denaturation step of 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 5 sec and annealing/extension at 60°C for 1 min. A delta-delta approach was used for the qRT-PCR analysis.

Cell sequencing

RNA extracted from the same 12 cases was used to do whole transcriptome sequencing and differential analyses, comparing WCDS versus WTH. Sequencing libraries were prepared with 100 ng of total RNA using Illumina's Truseq RNA Sample Preparation Kit v2 (Illumina, Inc.) following the manufacturer's protocol. The final library was sequenced by 2 x 75 bp paired-end sequencing on a HiSeq 2500, aiming for 25 M read

per samples. After sequencing, FASTQs files were processed using STAR and HTSeq, obtaining a count table summarized at the gene level. Raw counts were filtered for genes with average counts less than five and were normalized using DESeq2 (PMID: 25516281). The differential analysis was conducted with DESeq2 using a paired design, and we selected the differentially expressed genes by FDR<0.01 and \log_2 FC>|1.5|, aiming to include all the genes most differentiated between the two groups [13,14]. We classified the genes according to their specific cell expression signatures using a single cell mRNA database from the mouse cortex [15]. Using these data, we defined an enrichment score based on deconvolution of the known relative expression of genes in different cell types, thus assigning each gene transcript to a specific cell (neuron, astrocyte, microglia, endothelial cell, and oligodendrocytes) or a "mixed" category when the expression was not specific to any cell type [16,17]. Data available on synapse (https://www.synapse.org/#!Synapse:syn25666186).

Results

The resulting yield of WCDS was roughly 16 million cells per gram of fresh human gray matter. Paraffin-embedded cell pellets were stained with H&E for nuclear morphology and immunohistochemically stained with antibodies specific for neurons (neurofilament, Neu N), astrocytes (glial fibrillary acidic protein, GFAP) and microglia (lba1) to confirm that major cell types were present. Each examined dissociated cell suspension always had a diverse population by nuclear morphology typically including approximately 40% neurons, 25% astrocytes, 21% microglia, 5% oligodendrocytes, and 4% endothelial cells. Cell soma was intact; astrocytes occasionally had attached cell processes, while these were less common in neurons and microglia.

Our cell suspension also had detached processes, but for the purpose of this study we did not attempt beyond initial centrifugation steps to further remove them from the suspensions. Cell surface and intracellular cell-specific antigen were preserved in all examined WCDS, which allowed us to also separate cell-specific populations by FACS and confirm similar percentages of neurons, astrocytes, and microglia (Figure 2).

Accutase enzymatic digestion was optimal at 4 hrs at 4°C, as judged by the RNA integrity and ability to create dissociated suspensions without clumps. RIN for unfixed WCDS incubated for 4 hrs in enzyme ranged from 2 to 8, with a mean RIN of 6.2 and 2.1 standard deviations, while 2 hrs incubations resulted in an average RIN of 4.8+/-3.3 and no enzyme incubation 2.7+/-0.07. The yield of RNA ranged from 4-350 ng/million cells, with a mean yield of 55 ng/million cells. Similarly, RIN from methanol-fixed WCDS that were incubated in enzyme for 4 hrs ranged from 2 to 10, with a mean RIN of 5+/-3.6 and a yield of 60 ng/million cells +/-101. RNA extraction from WCDS and WTH was done on the 12 randomly selected cases. RIN meansfor those 12 WCDS were 6.3+/-2.0, while WTH had a RIN mean of 6.5+/-2.0. qRT-PCR results suggest that neuronal NEU-N and astrocyte GFAP RNA expression were not different between WCDS and WTH, while RNA expression of the well-known microglia protein IBA1 was up regulated in WCDS (Figure 3).




Figure 2. Fluorescence-activated cell sorting (FACS) of whole-cell suspensions labeled with NeuN, GFAP, and IBA1 (above). Note: FACS allowed separation (S-P in all 3 panels above) of cells fluorescing with both a non-specific nuclear stain (488 nm, x-axis) and cell-type-specific antibodies (647 nm, Y-axis). The collection of these cells would allow further transcriptomic and proteomic analysis of specific cell populations.




Figure 3. RNA transcript analysis of cell suspensions and adjacent intact brain tissue by qRT-PCR and RNAseq. Note: A. qRT-PCR demonstrating the presence of transcripts for NeuN, GFAP, OLIG2, and Iba1in WCDS; B. WCDS express more than 11,000 different gene transcripts, including transcript specific for neurons (N), astrocytes (A), oligodendrocytes (O), microglia (M),and endothelial cells (E). When WCDS is compared to adjacent frozen whole tissue homogenates of the same cases, the total count of transcript per gene was similar, suggesting minimal transcript loss caused by the dissociation process.

The same twelve cases were also used to do whole transcriptome sequencing and differential analyses, comparing Sorted Cells versus Homogenates. We classified the genes according to their specific cell expression signatures using a single cell mRNA database from the mouse cortex. Using these data, we defined an enrichment score based on deconvolution of the known relative expression of genes in different cell types, thus assigning each gene transcript to a specific cell (neuron, astrocyte, microglia, endothelial cell, and oligodendrocytes) or a "mixed" category when the expression was not specific to any cell type [16]. We successfully sequenced more than 11,000 gene transcripts per WCDS. The average total mapped reads were 18,283,887 in the WCDS and 7,418,515 in WTH. Transcripts in WCDS and WTH included many that are specific for neurons (n=626), astrocytes (n=375), oligodendrocytes (n=316), microglia (n=684), endothelial cells (n=578) and non-cell-specific transcripts (n=8,173). When cell-specific WCDS transcripts expression were compared (n=9,820) to WTH, several transcripts were upregulated or downregulated, but most numbers of cell-specific transcripts had a similar expression in both groups. The most evident differences were in microglia-specific genes, where almost 50% of the sequenced genes showed upregulation, and in neurons, where 40% of the neuron-specific genes were down regulated or expressed at lower levels in the dissociated cell preparations as compared to the whole cortical homogenates Upregulation and downregulation were defined as 1.5 log, fold change in either direction. Only a handful of genes reached a 5 log, fold change and were microglia-specific [18-22] (Figure 4).




Figure 4. Sequenced transcripts from WCDS and WTH classified by cell expression signatures. Note: Specific cell expression signatures using a single cell mRNA database from mouse cortex allow us to subdivide transcripts by cell-type or mixed (present in two or more cell types). For most cell types, transcript abundance was similar between WCDS and WTH (grey bar). Microglial-enriched suspension transcripts showed up regulation (purple) in almost 50% of the transcripts, while approximately 40% of neuron-specific transcripts were down-regulated (blue). Up regulation and down regulation were defined as 1.5 \log_2 fold change in either direction.

Discussion and Conclusion

The scientific community now has many powerful tools to study genetic and transcriptomic changes in the human brain and disease. However, most studies using such techniques have been in whole-tissue homogenates; we now recognize that studying millions of various types of cells together, most with different transcriptomic profiles, could confound and obscure our understanding of the relevant functional pathways and regulations. LCM and single-nuclei methods have highlighted the importance of extending transcriptomic studies to a single-cell level by isolating phenotypicallydefined populations to capture small changes that might be masked when compared with bulk tissue homogenizations. Such studies have revolutionized the field, and even though there are already intriguing results published from singlenucleus studies of human brain cells, there have been very few similar studies of human whole cell preparations. Results from different methodologies could complement each other; for example, single-nucleus preparations might result in more or quicker sequencing data than using LCM technology and is more widely accessible through archived frozen tissue, but nuclear mRNA is less abundant and may not represent the entire cellular complement. In addition, many of the nuclear isolation studies can't successfully obtain all types of human brain cells such as microglia. Having WCDS preparations allows us to study transcripts present in both nuclei and cytoplasm, without compromising quantity, speed, and quality of data generation. We collected cells suspended in 30%-70% percol gradients always and had a diverse population by nuclear morphology typically including approximately 40% neurons, 25% astrocytes, 21% microglia, 5% oligodendrocytes, and 4% endothelial cells. With larger neurons migrating more toward the 30% gradient and small glial cell precent at denser gradient layer (~70%).

In this study, we explored a new methodology to create WCDS at cold temperatures from a rapidautopsy brain collection program that will serve as a new shared resource for researchers interested in cell population changes in aging and aging-related disorders. Transcriptional processes remain active at 37°C, therefore it has been hypothesized that cell dissociation in cold temperatures could limit gene expression artifact created by the tissue preparation methods, which might be expected to upregulate stress response genes. To investigate this, we compared the transcriptome of twelve WCDS to WTH from the same cases to identify possible changes created by processing. Our data shows that our suspensions contain relatively intact brain cells of several different types, with good yields of RNA and relatively good RIN values. We demonstrated that the RNA isolated from such suspensions is suitable for sequencing, and our results suggest that rather than losing transcripts during the WCDS processing, we captured a higher number of mapped transcripts than with the WTH samples. As this was surprising, we hypothesize that WCDS-RNA is derived mainly from cellular perikarya, which have more abundant transcripts than cell processes or neurites and would be a more substantial contributor to WTH-RNA. In this study we did not compare results from isolated nuclei, but we proposed that sequencing WCDS should contain

higher transcript numbers per cell. Our results suggest that this new resource will be valuable and probably complementary to other resources to study cell-type-specific changes in aging and agingrelated disorders. Some of these transcripts, when present in both WCDS and WTH prepara were expressed at a higher or lower abundance in one source or the other. Overall, most transcripts were very similar between WCDS and WTH, but it is an important finding that almost 50% of the microglia-specific genes showed upregulation in the dissociated cell preparations when compared to the whole cortical homogenates. Even though our procedure is performed in a cold environmentto reduce transcriptomic changes, microglia might still be reactive to the dissociation procedure, resulting in the upregulation of specific transcripts. Therefore, caution should be taken in interpreting future studies using isolated microglia.

References

- Darmanis, Spyros, Sloan Steven A, Zhang Ye and Enge Martin, et al. "A Survey of Human Brain Transcriptome Diversity at the Single Cell Level." Proc Natl Acad Sci 112 (2015): 7285-7290.
- Guez-Barber, Danielle, Fanous Sanya, Harvey Brandon K and Zhang Yongqing, et al. "FACS Purification of Immunolabeled Cell Types from Adult Rat Brain." J Neurosci Methods 203 (2012): 10-18.
- Otero-Garcia, Marcos, Xue Yue-Qiang, Shakouri Tamara and Deng Yongning, et al. "Single-Soma Transcriptomics of Tangle-Bearing Neurons in Alzheimer's Disease Reveals the Signatures of Tau-Associated Synaptic Dysfunction." bioRxiv (2020): 088591.
- Bakken, Trygve E, Hodge Rebecca D, Miller Jeremy A and Yao Zizhen, et al. "Single-Nucleus and Single-Cell Transcriptomes Compared in Matched Cortical Cell Types." PLoS One 13 (2018): e0209648.
- Lake, Blue B, Ai Rizi , Kaeser Gwendolyn E and Salathia Neeraj S, et al. "Neuronal Subtypes and Diversity Revealed by Single-Nucleus RNA Sequencing of the Human Brain." Science 352 (2016): 1586-1590.
- Lake, Blue B, Codeluppi Simone, Yung Yun C and Gao Derek, et al. "A Comparative Strategy for Single-Nucleus and Single-Cell Transcriptomes Confirms Accuracy in Predicted Cell-Type Expression from Nuclear RNA." Sci Rep 7 (2017): 6031.
- Srinivasan, Karpagam, Friedman Brad A, Etxeberria Ainhoa and Huntley Melaine A, et al. "Alzheimer's Patient Microglia Exhibit Enhanced Aging and Unique Transcriptional Activation." Cell Rep, 31 (2020): 107843.
- Celis, Ktrina, Griswold Anthony J, Bussies Parker L and Rajabli Farid, et al. "Transcriptome Analysis of Single Nucleus RNA-Seq from Alzheimer Disease APOE4 Carrier Brains in African American (AA) and Non-Hispanic Whites (NHW) Reveals Differences in APOE Expression (4626)." Neurology 94 (2020): 4626
- Mathys, Hansruedi, Davila-Velderrain Jose, Peng Zhuyu and Gao Fan, et al. "Single-Cell Transcriptomic Analysis of Alzheimer's Disease." Nature 570 (2019): 332-337.

- Zhou, Yingyue, Song Wilbur M, Andhey Prabhakar S and Swain Amanda, et al. "Human and Mouse Single-Nucleus Transcriptomics Reveal TREM2-Dependent and TREM2-Independent Cellular Responses in Alzheimer's Disease." Nature Medicine 26 (2020): 131-142.
- Beach, Thomas G, Adler Charles H, Sue Lucia I and Serrano Geidy, et al. "Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program." Neuropathology 35 (2015): 354-389.
- Beach, Thomas G, Sue Lucia I, Walker Douglas G and Roher Alex E, et al. "The Sun Health Research Institute Brain Donation Program: Description and Experience, 1987-2007." Cell Tissue Bank 9 (2008): 229-245.
- Alles, Jonathan, Karaiskos Nikos, Praktiknjo Samantha D and Grosswendt Stefaine, et al. "Cell Fixation and Preservation for Droplet-Based Single-Cell Transcriptomics." BMC Biol 15 (2017): 44.
- Hochberg, Yosef and Benjamini Yoav. "Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing." J R Stat Soc 57 (1995): 289-300.
- Love, Michael I, Huber Wolfgang and Anders Simon. "Moderated Estimation of Fold Change and Dispersion for RNA-Seq Data with DESeq2." Genome Biol 15 (2014): 550.
- 16. Zhang, Ye, Chen Kenian, Sloan Steven A and Bennett Mariko L, et al. "An RNA-Sequencing Transcriptome and Splicing Database of Glia, Neurons, and Attending the Central Hospital of Yaounde, Cameroon." Afr J Clin Exper Microbiol 11 (2010): 174-178.
- Piras, Ignazio S, Bleul Christiane, Talboom Joshua S and De Both Matthew, et al. "ESHRD: Deconvolution of Brain Homogenate RNA Expression Data to Identify Cell-Type-Specific Alterations in Alzheimer's Disease." Aging (Albany NY) 12 (2020): 4124-4162.
- Zhang, Ye, Sloan Steven A, Clarke Laura E and Caneda Christine, et al. "Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse." Neuron 89 (2016): 37-53.
- Fujita, J. "Cold Shock Response in Mammalian Cells." J Mol Microbiol Biotechnol 1 (1999): 243-255.
- O'Flanagan, Ciara H, Campbell Kieran R, Zhang Allen W and Kabeer Farhia, et al. "Dissociation of Solid Tumor Tissues with Cold Active Protease for Single-Cell RNA-Seq Minimizes Conserved Collagenase-Associated Stress Responses." Genome Biology 20 (2019): 210.
- Sonna, Larry A, Fujita Jun, Gaffin Stephen L and Lilly Craig M. "Invited Review: Effects of Heat and Cold Stress on Mammalian Gene Expression." J Appl Physiol (1985) 92 (2002): 1725-1742.
- Volovitz, Ilan, Shapira Netanal, Ezer Haim and Gafni Aviv, et al. "A Non-Aggressive, Highly Efficient, Enzymatic Method for Dissociation of Human Braintumors and Brain Tissues to Viable Single-Cells." BMC Neurosci 17 (2016): 30.

How to cite this article: Serrano, E Geidy, Jessica E Walker, Anthony J Intorcia and Michael J Glass, et al. "Whole-Cell Dissociated Suspension Analysis in Human Brain Neurodegenerative Disease: A Pilot Study." J Tiss Sci Eng 12 (2021): 242.